Figure 3 | Eye

Figure 3

From: Erratum: Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results

Figure 3

Distribution of the first measured interval after loading doses (horizontal axis), plotted against the last applied interval at month 24 (vertical axis), for all eyes that underwent treatment with ranibizumab for neovascular age-related macular degeneration according to the studied regimen ‘observe and plan’. The term ‘observation’ is equivalent to any interval longer than 3 months. These eyes were followed regularly without planned injection.

Back to article page